<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FE0D06D3-8E96-4D18-B531-03C370F0D6CB"><gtr:id>FE0D06D3-8E96-4D18-B531-03C370F0D6CB</gtr:id><gtr:firstName>Jadwiga</gtr:firstName><gtr:otherNames>Anna</gtr:otherNames><gtr:surname>Wedzicha</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800570"><gtr:id>3DDFCE94-17B5-4C9C-A074-13F8BC5A2DF0</gtr:id><gtr:title>THE LONDON COPD EXACERBATION COHORT (The EXCEL Cohort)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800570</gtr:grantReference><gtr:abstractText>Patients with chronic obstructive pulmonary disease (COPD) may often experience episodes of acute worsening of symptoms called exacerbations or ?attacks?. These exacerbations are an important cause of physical and mental ill-health, poor quality of life and death. Exacerbations also impose a considerable cost on the NHS, the patient and their families through time off work, hospital admissions and additional treatments. Finding the cause of these episodes is difficult because they can be due to different types of bacteria and viruses, and their timing is unpredictable so that the patient must be seen as soon as possible after the start of the infection. There is still an urgent need for more studies of COPD exacerbations but researchers need access to patients in whom exacerbations are likely to occur.

The London COPD Exacerbation Cohort (EXCEL Cohort) is a small established cohort of COPD patients recruited and specifically trained and monitored to report their attacks (exacerbations) to the research team to enable the exacerbation to be studied (and also the patient to receive treatment as quickly as possible). Our skills in running this cohort and research that we have published has gained us an international reputation and we have received both charity and industry research grants over the last 10 years. We are now seeking funding to increase the size of our cohort from 150 to 300 patients, and to study our patients in even greater detail with investigations including x-ray scanning measures of thickness of the lung airways and emphysema, state-of-the-art detection of bacteria and viruses using modern molecular methods, airway and systemic inflammation and ultrasound imaging of the heart. This will provide important information that will allow new treatments and ideas to be tested more efficiently. Our cohort has previously been involved in many studies, both on our own and in collaboration with other researchers world-wide. This proposed enlargement of our cohort has received support from multi-national pharmaceutical companies and the NHS as it provides a cost-effective resource to carry out smaller studies on specific groups of COPD patients.</gtr:abstractText><gtr:technicalSummary>Chronic obstructive pulmonary disease (COPD) exacerbations are acute episodes of worsening symptoms and an important cause of morbidity and mortality associated with the condition. They are also a major outcome measure for therapeutic intervention studies. The triggers and mechanisms of COPD exacerbations are still not clearly understood and more study of exacerbations is required if the economic and health burden of these disease is to be reduced. Exacerbations are heterogeneous in severity, occur unpredictably and must be sampled early before they are treated and resolve. Thus studies of COPD exacerbations must have access to patients who develop exacerbations and who are trained in detection and reporting of these exacerbations to the study team. 

The London COPD Exacerbation Cohort (EXCEL Cohort) is an established cohort designed to study mechanisms of COPD exacerbations and their impact on health status and disease progression. Our work has contributed greatly to the understanding of COPD exacerbations. The cohort has already participated in observational studies, proof of concept studies, both grant funded and industry funded, to reduce the frequency and severity of these important events. We will utilize our existing strengths for accurately determining exacerbation frequency and severity with robust methodology previously developed by our group. Patients will be trained to monitor their symptoms electronically and detect and report exacerbations promptly, so that their exacerbations can be sampled early after symptom onset. With the specific funding, the cohort will be increased to recruit a total of 300 COPD patients, who will be phenotyped on the basis of exacerbation frequency, usual long term therapy, lung function, health status and psychological function, airway bacterial and viral infection by quantitative molecular methods. The funding requested will allow further phenotyping by CT scanning on the basis of airway wall thickness and emphysema, novel airway and systemic inflammatory markers and cardiovascular function. The exacerbation cohort will be suitable for epidemiological studies of the natural history and mechanisms of exacerbations, interventions to reduce exacerbation severity and frequency and also studies of interventions to treat individual exacerbations. Enlargement of our cohort has received support from two multi-national drug companies as it provides them with a cost-effective resource to carry out targeted proof of concept trials on specific groups of COPD patients.</gtr:technicalSummary><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>566067</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Southampton</gtr:department><gtr:description>Airway epithelial cell studies in COPD</gtr:description><gtr:id>A0C8F67C-982D-4DBC-817C-29C6CB5ACC8E</gtr:id><gtr:impact>Success in MRC/ABPI call</gtr:impact><gtr:outcomeId>VLnjmdrJrc9-1</gtr:outcomeId><gtr:partnerContribution>Development of other grant applications</gtr:partnerContribution><gtr:piContribution>COPD patients under go bronchoscopies and material available for collabortaive work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>MRC ABPI COPD Collaboration</gtr:description><gtr:id>59F2A2F0-B00D-46B1-BC9D-D84D2A196BEB</gtr:id><gtr:impact>Contracts now signed and work packages under way</gtr:impact><gtr:outcomeId>fhCXk8nAukh-1</gtr:outcomeId><gtr:partnerContribution>Enabled the MRC ABPI consortium</gtr:partnerContribution><gtr:piContribution>Major part of this collaboration and the London COPD cohort is the main source of patient study and clinical samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>RSV infection and co-morbidity</gtr:description><gtr:id>961E48BA-EE3C-41D3-BE10-10BAAC7FEC88</gtr:id><gtr:impact>In progress
Abstracts to be presented at meetings.
papers in preparation</gtr:impact><gtr:outcomeId>PMpgZqQ7sik-1</gtr:outcomeId><gtr:partnerContribution>Collaborators have provided experience on immunology of RSV</gtr:partnerContribution><gtr:piContribution>Provide COPD patients from cohort that are wekll phenotyped. Studies of viral and bacterial infection and airway and systemic inflammatory markers</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>Inflamamtory Therapeutic Capability Clusters (TRPs)</gtr:description><gtr:id>4B26B01C-AE53-4D55-A5F9-146EEE0AA9D0</gtr:id><gtr:impact>Collaboration recently commenced</gtr:impact><gtr:outcomeId>VRTL5WxDHsa-1</gtr:outcomeId><gtr:partnerContribution>The Capability Cluster has been awarded to centres in the UK and we are one of the Centres - this includes Imperial, Nottingham, Manchester, KGT, Leicester, Southampton</gtr:partnerContribution><gtr:piContribution>Developed the first protocol for drug development</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>Studies of macrophage phagocytosis in COPD</gtr:description><gtr:id>22E34490-2E1A-4BC7-AA07-34B45E02DD04</gtr:id><gtr:impact>Original Paper published</gtr:impact><gtr:outcomeId>da1fjhR5ABT-1</gtr:outcomeId><gtr:partnerContribution>Expertise in phagocytosis experiments</gtr:partnerContribution><gtr:piContribution>Provision of samples form well phenotyped patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Statistical modelling of COPD exacerbations</gtr:description><gtr:id>2B721429-4F92-45BB-BF6C-F99461FED140</gtr:id><gtr:impact>Abstract submitted to meeting of American Thoracic Society emeting in Denver, USA 2011</gtr:impact><gtr:outcomeId>MiHG7JMhTZ8-1</gtr:outcomeId><gtr:partnerContribution>new developments - paper in preparationnew developments - paper in preparation</gtr:partnerContribution><gtr:piContribution>Our COPD data used directly for this collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Epidemiology, Biostatistics and Occupational Health</gtr:department><gtr:description>Statistical modelling of COPD exacerbations</gtr:description><gtr:id>A45336B2-77CF-4CD4-AE2A-2BD50E171D2F</gtr:id><gtr:impact>Abstract submitted to meeting of American Thoracic Society emeting in Denver, USA 2011</gtr:impact><gtr:outcomeId>MiHG7JMhTZ8-2</gtr:outcomeId><gtr:partnerContribution>new developments - paper in preparationnew developments - paper in preparation</gtr:partnerContribution><gtr:piContribution>Our COPD data used directly for this collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient groups</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7444C989-1C0B-4EC1-B18B-7F4E0CECF1B4</gtr:id><gtr:impact>Open day in Camden PCT for patients with COPD. My group presented on COPD and our research activities

Increased patient recruitment</gtr:impact><gtr:outcomeId>YzC9HGBB8dr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient cohort meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>82D45380-6744-45AA-AD2C-0EE31BC77759</gtr:id><gtr:impact>Regular meetings of our research cohort, where we discuss studies and also future ones. Review protocols etc.,</gtr:impact><gtr:outcomeId>58c479f26d7543.43703285</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLF Project grants</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>31A23760-598D-4FAE-817D-E3800C8C7078</gtr:id><gtr:outcomeId>SXg5UmUVboA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>212000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Fellowship</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8B759C64-A41D-480C-AFA3-F40CFA2C0DA7</gtr:id><gtr:outcomeId>FdpPxKMXV6P0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>621000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Population Scientist Award</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F1EC8BEF-B694-4CC8-A226-C80BFED6CC2F</gtr:id><gtr:outcomeId>Kd9BHh3XJUG0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Applied Programme Grant</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>FA143870-ECB9-47E3-A7E9-E9129D3D9AD1</gtr:id><gtr:outcomeId>WEyBpYxSVej0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE COPD guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3A3489C1-0829-4C2B-9BD9-1F83AAB5E715</gtr:id><gtr:impact>We have shown the importance of exacerbations in COPD and why they are an important outcome in studies for clinical and economic reasons.</gtr:impact><gtr:outcomeId>4F13A5CF7BD</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of NICE Quality Standard Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D40C4B39-D6CE-44D8-87D7-470CC0A2837F</gtr:id><gtr:impact>Development of NICE Quality standards relating to COPD exacerbations</gtr:impact><gtr:outcomeId>hHSVeBZENmz</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of DoH Respiratory Programme Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>59005E04-7789-4C44-9C16-07F4EC17F220</gtr:id><gtr:impact>Our experience with the cohort enabled influence on matters relating to COPD exacerbations</gtr:impact><gtr:outcomeId>D7s5sSdZzyg</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>COPD strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CFC22A8-CE3F-4F86-B110-437B4487A487</gtr:id><gtr:impact>I am a member of the programme Committee for the COPD srategy and clinical lead for the Home Oxygen Service. our cohort work has influenced both acute and chronic care within the strategy.</gtr:impact><gtr:outcomeId>D262AFFC3A2</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Respiratory Society COPD exacerbation Guideline Committee/Chair</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2C104118-2B99-4811-9228-4A0B31B0AC3C</gtr:id><gtr:impact>Chair of group developing guidelines on COPD exacerbations</gtr:impact><gtr:outcomeId>XGoRm9zXUsc</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citations in reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>115C4688-C91D-4A8B-B4B6-C4B0856076EE</gtr:id><gtr:impact>The paper by Hurst et al from the cohort shows the improtance of exacerbation clustering and why follow up is important after hospital admission and exacerbation.</gtr:impact><gtr:outcomeId>57FB7D6674F</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Funding awarded to Dr John Hurst (applicant on MRC grant) for development of oximetry</gtr:description><gtr:id>3B407707-70CC-4C51-98BD-8FFA3825B075</gtr:id><gtr:impact>Published in peer review journal and presented at internatioal conference</gtr:impact><gtr:outcomeId>RVKFBzfDF17</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Evaluation of domiciliary pulse oximetry</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a daily diary card for patient use to detect exacerbations and reprot them promptly to healthcare professionals</gtr:description><gtr:id>E00D5C43-97F5-47DB-ADDE-B1FCE9BDFEA9</gtr:id><gtr:impact>This diary has been used to diagnose, define and detect exacerbations by other research groups.</gtr:impact><gtr:outcomeId>F5F8334D6A7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>COPD cohort diary</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We validated the use of e-monitoring for the detection of exacerbation symptoms and thus presentation</gtr:description><gtr:id>30548079-058A-46CF-8CB5-471181765A32</gtr:id><gtr:impact>This is now being used in a randomised contrilled trial in COPD patients</gtr:impact><gtr:outcomeId>pbr1MQoCLTi</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>e-technology health diary using Blackberry</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We developed a COPD database for the cohort data and including the daily diary card data.</gtr:description><gtr:id>D12E60BD-74BF-4095-9F3D-05899BFA3AEA</gtr:id><gtr:impact>This database has allowed us to collect and analyse the data form the cohort more effiiciently and accurately.</gtr:impact><gtr:outcomeId>EEA90622DCE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>COPD database</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0475D8A4-5EB5-466E-B06F-EE3AFF9D6385</gtr:id><gtr:title>Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b1723e0498997675037f550ba7ba764"><gtr:id>3b1723e0498997675037f550ba7ba764</gtr:id><gtr:otherNames>Quint JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>0DCCF80E061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB05D575-4265-4030-8750-68E5D500DB3D</gtr:id><gtr:title>Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c477658d4fd4.26021792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>762C90A7-5852-4485-8178-BE6F485357BC</gtr:id><gtr:title>Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>54637ea66f0ea5.47050862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB2E1C00-8F72-4B15-8087-0F4EF2EA3A81</gtr:id><gtr:title>Efficacy of roflumilast in the COPD frequent exacerbator phenotype.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>pm_16417_27_23117188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>079DF2EA-0D32-496D-A1FA-5947F68EE31E</gtr:id><gtr:title>Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6307dbd9b4ae066c0baaf12c18506016"><gtr:id>6307dbd9b4ae066c0baaf12c18506016</gtr:id><gtr:otherNames>Bewley MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c477677823f6.37824265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13809DE2-EE7F-44C9-B6C1-83AB0B5660C2</gtr:id><gtr:title>Time course and pattern of COPD exacerbation onset.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ee12bdaf2641a73c135c3606fcfc18f"><gtr:id>1ee12bdaf2641a73c135c3606fcfc18f</gtr:id><gtr:otherNames>Aaron SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>DCDkNkgCuje</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18AFB71E-C94D-4044-9AB0-CCDB2967BE90</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47765e17239.80169858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C62B243-6255-4266-AED2-E209E9DEC141</gtr:id><gtr:title>Blood eosinophils and inhaled corticosteroid/long-acting ?-2 agonist efficacy in COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/196260af99aec105dadcc0b8ace298d9"><gtr:id>196260af99aec105dadcc0b8ace298d9</gtr:id><gtr:otherNames>Pavord ID</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58c47593ef04a9.86768348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51E65D9-617D-4C93-BDFB-71D8E56C1678</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.</gtr:title><gtr:parentPublicationTitle>Archivos de bronconeumologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-2896</gtr:issn><gtr:outcomeId>58c47764aea073.45250496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E661CFF-57FB-4321-9863-9F2D1AC5845A</gtr:id><gtr:title>Deprivation, winter season, and COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>Primary care respiratory journal : journal of the General Practice Airways Group</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4418</gtr:issn><gtr:outcomeId>pm_16417_27_23959046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E55F649-CD61-486C-BAA9-E2065FBE2421</gtr:id><gtr:title>Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c4758fc7bae2.42537667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3677B52F-1A90-41DF-BB90-DD2E52B81595</gtr:id><gtr:title>Influence of season on exacerbation characteristics in patients with COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>ZCc47H213iw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>025EBCDB-E7ED-4D2A-96A9-DF5BB677A1BA</gtr:id><gtr:title>Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>58c47590df6791.54009636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>384B43FA-6E03-4E37-8550-BAEBD661D2BA</gtr:id><gtr:title>The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ffe59fc47e844902206e70ad18bb1b3"><gtr:id>1ffe59fc47e844902206e70ad18bb1b3</gtr:id><gtr:otherNames>Allinson JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47593aa6ec2.07000870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D910DF-FA39-46C5-83F0-081BCD847A4C</gtr:id><gtr:title>Predicting In-Hospital Treatment Failure (= 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f73cd47ec8e43d9d3734666f444e5219"><gtr:id>f73cd47ec8e43d9d3734666f444e5219</gtr:id><gtr:otherNames>Crisafulli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>58c47594364bd3.06220809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6944FD29-F0FD-4542-98A0-5F0680DC7EB7</gtr:id><gtr:title>Increased risk of myocardial infarction and stroke following exacerbation of COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>K8nBk8LzAdH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7900E500-26A7-4E83-BE1F-CA9D2A5AB696</gtr:id><gtr:title>Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44262b2dce43af0a517a8d9359049458"><gtr:id>44262b2dce43af0a517a8d9359049458</gtr:id><gtr:otherNames>Rodriguez-Roisin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47767b978a4.27851056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7BCEF2B-2F30-46EC-82C3-44239E4C2449</gtr:id><gtr:title>Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/904f884f2cedac3bc8311c15aeb35f7b"><gtr:id>904f884f2cedac3bc8311c15aeb35f7b</gtr:id><gtr:otherNames>Wang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a9ea16c9d3132.43982122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D0ED5DC-11E0-47DA-99FF-0C69E5B9A91F</gtr:id><gtr:title>Physical activity and exercise capacity in patients with moderate COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58c4759134a6d4.57127566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72742E27-CE3A-4AA5-94E7-EC762273D7A9</gtr:id><gtr:title>Susceptibility to exacerbation in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>TmkqUCdAEdR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68C9682B-C142-492D-89AC-B7CF542BF690</gtr:id><gtr:title>Outdoor air pollution and respiratory health in patients with COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f978431cfb6605052f84744a62a87a3"><gtr:id>8f978431cfb6605052f84744a62a87a3</gtr:id><gtr:otherNames>Peacock JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>shLGLHbiEXx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06727CDF-B0CF-4F6C-8EC3-2EEB30A56F0E</gtr:id><gtr:title>Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68361379cb4d5e44a6e7514c816ffa78"><gtr:id>68361379cb4d5e44a6e7514c816ffa78</gtr:id><gtr:otherNames>Garcha DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_16417_27_22863758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E11448CD-AA83-417C-A09C-C647E50BF243</gtr:id><gtr:title>Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_16417_27_22323575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCDFE726-F69C-4F36-B212-120D33F7B687</gtr:id><gtr:title>Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>qbXWAFcCYZ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EAF1AE1-6E08-4F82-94BF-0116D379E542</gtr:id><gtr:title>Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee254fd9228e84336f32ea52d5b8010"><gtr:id>bee254fd9228e84336f32ea52d5b8010</gtr:id><gtr:otherNames>Patel AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16417_27_24033321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3C83107-7C18-4D50-8E48-958C5BEEAD41</gtr:id><gtr:title>Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca86c3c81818d7fb4a9a6f23229a4a3"><gtr:id>4ca86c3c81818d7fb4a9a6f23229a4a3</gtr:id><gtr:otherNames>Han MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a9ea34c25d9d7.84383275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1862359E-B90E-4844-B42C-738B6FE24DBF</gtr:id><gtr:title>Relationship between depression and exacerbations in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b1723e0498997675037f550ba7ba764"><gtr:id>3b1723e0498997675037f550ba7ba764</gtr:id><gtr:otherNames>Quint JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>fMFUEy2zx5R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C591B7A-6E83-4BC3-AAD2-742E51D0FB88</gtr:id><gtr:title>Roflumilast: a review of its use in the treatment of COPD.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>58c4759474bca5.89804837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A73B48F-1B8E-40A0-821B-A28DDE37E95B</gtr:id><gtr:title>The potential value of biomarkers in diagnosis and staging of COPD and exacerbations.</gtr:title><gtr:parentPublicationTitle>Seminars in respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee254fd9228e84336f32ea52d5b8010"><gtr:id>bee254fd9228e84336f32ea52d5b8010</gtr:id><gtr:otherNames>Patel AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1069-3424</gtr:issn><gtr:outcomeId>XfepFE2JER9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4DE14D8-19EA-4E2D-9763-07CF39128E22</gtr:id><gtr:title>IL-1a/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc1b6575df668ed0494860d8b3ff64c"><gtr:id>7cc1b6575df668ed0494860d8b3ff64c</gtr:id><gtr:otherNames>Botelho FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16417_27_22163019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C97AC1BC-2927-44FA-A4DE-819DECAC413B</gtr:id><gtr:title>Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease &amp;quot;Super Exacerbators&amp;quot;.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47768056125.30590378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1192FCA3-637C-4BB0-8D98-625A7A95C0D3</gtr:id><gtr:title>Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16417_27_22281834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>683BDD0B-677D-4694-85D3-15999156236C</gtr:id><gtr:title>Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b58adb64320d9f920280ec466c001d1"><gtr:id>5b58adb64320d9f920280ec466c001d1</gtr:id><gtr:otherNames>Roche N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c4776467ffc4.96848265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA19304-2A0F-4798-AB27-EAC66271818D</gtr:id><gtr:title>Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b977aff7cd470e2bae6ebb89dafd132d"><gtr:id>b977aff7cd470e2bae6ebb89dafd132d</gtr:id><gtr:otherNames>Baghai-Ravary R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn><gtr:outcomeId>PMyL7p8acSx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D301EAA-A45F-45F2-A2A2-35DDF1B41A51</gtr:id><gtr:title>Sputum-to-serum hydrogen sulfide ratio in COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a73dad5029583cb0a79aaa583236afaf"><gtr:id>a73dad5029583cb0a79aaa583236afaf</gtr:id><gtr:otherNames>Saito J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>54637b32b87837.94337179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D87B419A-F9EE-41F9-B75D-B211342A5C1B</gtr:id><gtr:title>The role of complement activation in COPD exacerbation recovery.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn><gtr:outcomeId>58c477663f82d2.91273842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>874C2E38-D65A-4170-9A5B-7FC6BEFD4576</gtr:id><gtr:title>Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT).</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_16417_27_23988767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F81FD508-FA13-40F8-96BE-F20889E0D44F</gtr:id><gtr:title>Beta-blockers in COPD: time for reappraisal.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15ac1ceac61efae3b5e2b60458b2522f"><gtr:id>15ac1ceac61efae3b5e2b60458b2522f</gtr:id><gtr:otherNames>Lipworth B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58c47768432903.40428010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75FB1391-3FC1-4083-AC6C-511893AB60F4</gtr:id><gtr:title>How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11b830c588d08eee3ff3f298e8cf1e4c"><gtr:id>11b830c588d08eee3ff3f298e8cf1e4c</gtr:id><gtr:otherNames>Beeh KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47766d0dca5.12658897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F79175CD-00DD-45D4-BAA6-8E8305EB0A56</gtr:id><gtr:title>Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_16417_27_23945277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EA2067B-3CAD-4DF5-8555-5D2F76C9D98E</gtr:id><gtr:title>Temporal clustering of exacerbations in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>51B17ECD0E5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1F61B18-6AAC-4167-B7AE-16C51148C91C</gtr:id><gtr:title>25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b1723e0498997675037f550ba7ba764"><gtr:id>3b1723e0498997675037f550ba7ba764</gtr:id><gtr:otherNames>Quint JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>pm_16417_27_22726649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A16DFAD-1C08-4995-957D-DE39D9CE7D0B</gtr:id><gtr:title>Factors associated with change in exacerbation frequency in COPD.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>pm_16417_27_23899210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58884EB4-FC92-49F6-B934-8E05C9928DBC</gtr:id><gtr:title>The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4d866cc668c8c82c4062d2e2b6add7"><gtr:id>7a4d866cc668c8c82c4062d2e2b6add7</gtr:id><gtr:otherNames>Patel ARC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>ErSyquP29os</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC07DE14-CDA9-4367-8706-50725A567BA2</gtr:id><gtr:title>Hospitalized Exacerbations of COPD</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5adecef3dccad25e682025db1979f9b5"><gtr:id>5adecef3dccad25e682025db1979f9b5</gtr:id><gtr:otherNames>M?llerova H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>54637b3247ca26.76865428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0927CD2-A771-4CBF-A7D8-0CF492157E32</gtr:id><gtr:title>Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f4691d4afeba46a9833b90572523d93"><gtr:id>2f4691d4afeba46a9833b90572523d93</gtr:id><gtr:otherNames>Lawrence PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>58c47764f420b5.15773280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A75E2B-D216-49A2-B95F-3B15FA8DAF4B</gtr:id><gtr:title>Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/023c2cdabeda41d47594c3fe3de3b072"><gtr:id>023c2cdabeda41d47594c3fe3de3b072</gtr:id><gtr:otherNames>Jones RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>kaFVcUuzwtm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFE1395D-0705-4AD6-AD7D-9BDB253825AF</gtr:id><gtr:title>Predictive accuracy of patient-reported exacerbation frequency in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b1723e0498997675037f550ba7ba764"><gtr:id>3b1723e0498997675037f550ba7ba764</gtr:id><gtr:otherNames>Quint JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>mmXDnPkxb4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AB9DB31-39C9-4AE5-80F4-269127EF1A1B</gtr:id><gtr:title>Defective macrophage phagocytosis of bacteria in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ae09499f509debb276bcc0365bb8918"><gtr:id>0ae09499f509debb276bcc0365bb8918</gtr:id><gtr:otherNames>Taylor AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>6BD91EF5BDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F576C02-04AC-494A-8773-15CEB462EEBB</gtr:id><gtr:title>Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>58c47765483fc6.12203090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE89625E-7456-4908-ADD7-4BF06D5BE06F</gtr:id><gtr:title>Acute COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>Clinics in chest medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0272-5231</gtr:issn><gtr:outcomeId>54637a921d0467.34919669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B06910-4A2B-4A35-A99A-2FE3703C8DE6</gtr:id><gtr:title>Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>58c477668022e7.68659791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F271CCE-0053-49FE-A281-70008910B4F1</gtr:id><gtr:title>Daily activity during stability and exacerbation of chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>54637a91417673.67186768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>761FEC83-34AC-4652-8851-25AA01F8827B</gtr:id><gtr:title>Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>M49rbbt2SPv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7CD20D7-7356-40CB-83D7-DEE4B8B01D1A</gtr:id><gtr:title>Human rhinovirus infection during naturally occurring COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97199d1962a5578ab0e7f99245ae7020"><gtr:id>97199d1962a5578ab0e7f99245ae7020</gtr:id><gtr:otherNames>George SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>54637a91992b08.53846217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16D4BE2F-A45A-4FEA-BF8F-9BAAEE80CF1C</gtr:id><gtr:title>Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddd38ca11db008642251078e0d028a02"><gtr:id>ddd38ca11db008642251078e0d028a02</gtr:id><gtr:otherNames>Singh R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>54637b329449d9.56606322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E6D4A8-2C2E-4DE1-AB53-681B2CAA39F3</gtr:id><gtr:title>First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.</gtr:title><gtr:parentPublicationTitle>NPJ primary care respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343b1902ba6205692a14f688cda3d893"><gtr:id>343b1902ba6205692a14f688cda3d893</gtr:id><gtr:otherNames>Price D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2055-1010</gtr:issn><gtr:outcomeId>58c477671fbab0.73425456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC5A45D8-D701-4D8A-8194-3928F2FCDAC5</gtr:id><gtr:title>Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD.</gtr:title><gtr:parentPublicationTitle>Primary care respiratory journal : journal of the General Practice Airways Group</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-4418</gtr:issn><gtr:outcomeId>BV8jcSd4xB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0913893-99FC-419A-A112-DC386827D2A1</gtr:id><gtr:title>Blood and sputum eosinophils in COPD; relationship with bacterial load.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d54a68b07b2357e4c45ca19ed6669e"><gtr:id>07d54a68b07b2357e4c45ca19ed6669e</gtr:id><gtr:otherNames>Kolsum U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>5a9ea53ff06552.10673061</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800570</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>